Prospective study of exclusive strontium-/yttrium-90 beta-irradiation of primary and recurrent pterygia with no prior surgical excision. Clinical outcome of long-term follow-up

Strahlenther Onkol. 2009 Dec;185(12):808-14. doi: 10.1007/s00066-009-2000-1.

Abstract

Purpose: To evaluate the consecutive treatment results regarding pterygium recurrence and the efficacy of exclusive strontium-/yttrium-90 beta-irradiation for primary and recurrent pterygia and to analyze the functional outcome.

Patients and methods: Between October 1974 and December 2005, 58 primary and 21 recurrent pterygia were exclusively treated with strontium-/yttrium-90 beta-irradiation with doses ranging from 3,600 to 5,500 cGy. The follow-up time was 46.6 +/- 26.7 months, with a median of 46.5 months.

Results: The treatment led to a size reduction in all pterygia (p < 0.0001). Neither recurrences nor side effects were observed during therapy and follow-up in this study. Best-corrected visual acuity increased (p = 0.0064). Corneal astigmatism was reduced in recurrent pterygia (p = 0.009).

Conclusion: Exclusive strontium-/yttrium-90 beta-irradiation of pterygia is a very efficient and well-tolerated treatment, with remarkable aesthetic and rehabilitative results in comparison to conventional treatments, especially for recurrent lesions which have undergone prior surgical excision.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Astigmatism / radiotherapy
  • Beta Particles / therapeutic use*
  • Brachytherapy / instrumentation*
  • Esthetics
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Pterygium / radiotherapy*
  • Radiotherapy Dosage
  • Recurrence
  • Retreatment
  • Strontium Radioisotopes / therapeutic use*
  • Visual Acuity / radiation effects
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Strontium Radioisotopes
  • Yttrium Radioisotopes